Condition: Systemic Lupus Erythematosus · Inflammatory Myopathy · Systemic Sclerosis (SSc) · Sponsor: Peking University People's Hospital
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
This description comes directly from the study's public registry record.
Jing He · 010-88326666 · 569975536@qq.com
Always discuss trial participation with your own doctor first.
| Department of Rheumatology and Immunology, Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06794008